TrialCancer2019

Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.

Shreyaskumar Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.